Cyprotex (LSE: CRX) today announces that it has entered into an agreement with AstraZeneca AB (LSE:AZN) to provide drug discovery support.
Under the terms of the agreement, Cyprotex will investigate one of the key properties of potential drugs that determines the dose needed to elicit a therapeutic effect when given to a patient. This laboratory-based assay will be performed on compounds from AstraZeneca's early drug discovery projects and is one of a number of different technologies that Cyprotex uses to help partners evaluate and optimise the drug-like properties of candidate drugs.
Commenting on the agreement with AstraZeneca, David Leahy, CSO of Cyprotex said: "We have established a powerful combination of experimental and computational approaches for the early evaluation of compounds in drug discovery. This deal with AstraZeneca, a leading pharmaceutical company, further validates our developing science and technology platform."
Anders Tunek, Director of DMPK and Bioanalytical Chemistry at AstraZeneca R&D M�lndal, Sweden, said: "Cyprotex has presented a way for us to gain high quality data on our compounds with flexibility to meet our changing needs. We are very impressed by the capabilities that Cyprotex have developed and are looking forward to a close and productive collaboration."
For further information:
Dr David Leahy, CSO
Tel: +44 (0) 1625 505 100
Dr Anders Tunek
Director of DMPK and Bioanalytical Chemistry
AstraZeneca R&D M�lndal
Tel: +46 705 23 63 34
Henry Harrison-Topham/ Heather Salmond
Bankside Consultants Limited
Tel: +44 (0) 20 7444 4141